Cell & Gene Therapy Insights

What you will learn 01 How a triplex dPCR assay using short (83 bp) and long (345 bp) amplicons at the same locus combines absolute quantification of HEK293 residual DNA with median fragment size assessment in a single reaction 02 Why an extraction-free workflow maintains picogram-level sensitivity (LOQ 4 pg/reaction) and linearity across four orders of magnitude, including directly in conditioned HEK293 media 03 What an independent evaluation with viral process samples showed about skipping...

Nobel Prize in Physiology or Medicine 2026 was awarded for the discovery of light-gated ion channels and optogenetics; Conferences, events and publications.

A practical guide to resin selection for AAV anion exchange polishing, from pore accessibility to lot-to-lot consistency This interactive infographic examines how intra-resin pore architecture limits AAV polishing by anion exchange chromatography, comparing agarose, perfusion, monolith, and micrometer-pore resin formats.

“It is an area of unmet need, and that pushes the field to develop new therapies before every ‘i’ is dotted and every ‘t’ is crossed.” Abi Pinchbeck, Commissioning Editor, Cell & Gene Therapy Insights , speaks with William Matsui, Professor, MD Anderson Cancer Center, and Bryan McClellan, Postdoctoral Research Fellow, MD Anderson Cancer Center, about a recent Nature Communications study, conducted at UT Dell Medical School, on immunotherapy resistance in pancreatic cancer.

“We want to foster an environment of innovation and continue to develop conditions where developers and innovators can build that evidence base.” Fresh from his keynote at Advanced Therapies Europe, Abi Pinchbeck, Commissioning Editor, Cell & Gene Therapy Insights , speaks with Jacob George, Chief Medical and Scientific Officer, Medicines and Healthcare products Regulatory Agency (MHRA), about the MHRA’s evolving role in advanced therapy regulation, the UK’s position in the global CGT...

How do you take an electroporation-based cell engineering workflow off the research bench and turn it into a reproducible, clinical-scale manufacturing process? This session sows how a sustained academia-industry collaboration is bridging the gap, drawing on the UC San Diego program developing an autologous gene-edited hematopoietic stem cell (HSC) therapy for Friedreich's ataxia.

“...two of the obstacles patients with rare disease encounter first are the high costs associated with manufacturing and with getting into first-in-human trials.diseases...” Abi Pinchbeck, Editor, Cell & Gene Therapy Insights, speaks with Terence Flotte, Elisabeth Chair for the Dean of Medicine and Executive Deputy Chancellor of UMass Chan Medical School, past President of the American Society of Gene and Cell Therapy, about the origins of AAV-based gene therapy, the evolution of the field...

Cell & Gene Therapy Insights 2026; 12(9), 389–398 DOI: 10.18609/cgti.2026.043 Early automation decisions in adherent cell therapy manufacturing carry lasting consequences for cost, scalability, regulatory acceptance, and speed to clinic.

Cell and Gene Therapy Insights 2026; 12(9), 889–910 10.18609/cgti.2026.112 Recombinant adeno-associated virus (rAAV) has emerged as a leading platform for gene therapy, leveraging both naturally occurring and engineered capsids to deliver therapeutic transgenes. As clinical and research demand for rAAV has grown, vector quality and manufacturing consistency have become critical considerations.

Early-stage cell therapy companies face a series of process, workflow, and platform decisions well before IND, and each one shapes the likelihood of a successful clinical program. This panel discussion examines those decisions and the trade-offs behind them across various modalities, such as CAR-T, TIL, TCR, NK cell, and HSC-based therapies. Drawing on real-world examples, the panel explains how early technical choices affect comparability risk, regulatory expectations, and development timelines.